[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"death\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:death":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,43,79,104,130,176,211,237,266,290,318,343,380,413,438,458,490,527,559,589,623],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100473544","the-diaphragmatic-initiated-ventilatory-assist-diva-trial-100473544",false,"NCT05446272","The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial","DIVA","Inclusion Criteria:\n\n* Gestational age of 23 0\u002F7- 28 6\u002F7 weeks at birth\n* Intubated in the first 7 days of life\n* Undergoing extubation following at least 12 hours of invasive mechanical ventilation\n* Post-natal age \\\u003C32 weeks Post menstrual age at time of extubation\n\nExclusion Criteria:\n\n* Major congenital anomalies, including pulmonary hypoplasia\n* Neurologic disorders affecting respiratory drive (other than apnea of prematurity)\n* Esophageal bleeding or other contraindication to NG\u002FOG catheter placement\n* Current weight \\\u003C500 grams (based on Edi catheter approval)\n* Study ventilator not available at time eligibility criteria are met\n* Planned surgery or invasive procedure within 5 days of extubation\n* Informed consent not provided","ALL","0 Days","9 Weeks",{"count":20,"type":21},478,"ESTIMATED","INTERVENTIONAL",[24],"NA","DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 23 0\u002F7-28 6\u002F7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.",[27,28,29],"Extubation Failure","Bronchopulmonary Dysplasia","Death","RECRUITING","2026-06-24",{"date":33,"type":34},"2026-06-25","ACTUAL",{"date":36,"type":34},"2022-08-03",{"date":38,"type":21},"2027-12-31",{"name":40,"class":41},"University of Pennsylvania","OTHER",20,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100535528","radiofrequency-and-cryoablation-of-the-posterior-wall-of-the-left-atrium-100535528","NCT06253000","Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium","Comparative Analysis of Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium in Patients With Persistent Atrial Fibrillation","Inclusion Criteria:\n\n* Age over 18 years old;\n* Atrial fibrillation resistant to antiarrhythmic therapy;\n* Persistent and long-persisting form of atrial fibrillation;\n* The patient's consent to participate in the study.\n\nExclusion Criteria:\n\n* Age under 18 and over 80 years old;\n* The presence of another cardiac pathology requiring surgical treatment;\n* Congenital heart defects;\n* Previous \"open\" cardiac surgery;\n* Bone marrow diseases;\n* Pathology of the blood coagulation system;\n* The left ventricular ejection fraction is less than 40%;\n* Moderate to severe renal insufficiency (creatinine clearance \\\u003C50 ml\u002Fmin);\n* Drug-resistant hypertension (despite hypotensive therapy);\n* Organically altered mitral valve;\n* There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons;\n* The patient's participation in another clinical trial.","18 Years","80 Years",{"count":53,"type":21},158,[24],"Atrial fibrillation (AF) is the cause of 20% of strokes, and the risk of stroke in a person suffering from this arrhythmia increases by 5 times. Ischemic stroke in patients with AF is often fatal and, compared with stroke of other etiology, leads to the most pronounced disability and more often recurs. Accordingly, the risk of death in patients with AF-related stroke is 2 times higher, and treatment costs increase 1.5 times.\n\nThe main interventional method of treating AF, available in most medical institutions, is the use of radio frequency and\u002For cryoenergy to eliminate destructive damage to the left atrium (LA).\n\nThe aim of this study is to compare two different interventional methods and identify predictors of recurrence in patients with persistent and long-term AF.",[57,58,59,29,60],"Stroke","Acute Cerebrovascular Accident","Transient Ischemic Attack","Atrial Fibrillation Recurrent",[62,63,64,65,66,67],"atrial fibrillation","radiofrequency ablation","cryoablation","left atrium","the posterior wall of the left atrium","atrial remodeling","2026-05-07",{"date":70,"type":34},"2026-05-08",{"date":72,"type":34},"2023-06-10",{"date":74,"type":21},"2026-12-30",{"name":76,"class":77},"Bakulev Scientific Center of Cardiovascular Surgery","OTHER_GOV",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100454552","biomarkers-in-perioperative-management-100454552","NCT05199025","Biomarkers in Perioperative Management","Biomarkers to Guide Perioperative Management and Improve Outcome in High-risk Surgery","BIGPROMISE","Inclusion Criteria:\n\n* Cardiac surgery (isolated coronary artery bypass grafting or combined with single valve surgery, isolated single valve surgery)\n* Gastrointestinal surgery (colorectal, pancreatic, gastric surgery).\n* Vascular surgery (open and endovascular aortic surgery, peripheral vascular surgery)\n* Lung surgery (pneumonectomy,(bi)(sleeve)lobectomy or segmentectomy)\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy\n* Emergent surgery\n* No informed consent",{"count":88,"type":21},5000,"OBSERVATIONAL","Rationale: The rate of postoperative complications after high-risk surgery remains high despite recent advances in perioperative management. There is a lack of objective and reliable information that can be used for risk stratification and to guide treatment decisions.\n\nObjective: To describe the perioperative biomarker response in surgical patients with and without a postoperative complication and construct a preoperative and postoperative prediction model for postoperative complications. To systematically collect perioperative blood samples and clinical data in high-risk surgical patients for the development en analysis of biomarkers.\n\nStudy design: Multicenter, prospective, observational study. Study population: 4819 patients undergoing elective cardiac, colorectal, vascular and lung surgery.\n\nIntervention (if applicable): Not applicable. Main study parameters\u002Fendpoints: Main study parameters are levels of PCT, CRPhs, IL-6, GDF-15, sFLT, NT-proBNP, cTNThs, CysC and NGAL. Main study endpoint is the occurrence of a major postoperative complication which is defined as a surgical site infection, pneumonia, sepsis, acute kidney injury, major adverse cardiovascular events or death within 30 days of surgery.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: In each patient five blood samples will be drawn for analysis. Most of the blood samples are drawn simultaneously with routine perioperative laboratory testing, which is common in this study population. In case a patient is admitted to the Intensive Care Unit blood samples will be collected using an arterial line. There are no direct risks or benefits for patients included in the study.",[92,93,29],"Postoperative Complications","Quality of Life","2026-04-22",{"date":96,"type":34},"2026-04-27",{"date":98,"type":34},"2021-10-12",{"date":100,"type":21},"2026-12-01",{"name":102,"class":41},"St. Antonius Hospital",2,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":111,"targetDuration":113,"studyType":89,"phases":4,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":78},"100301866","registry-for-the-improvement-of-postoperative-outcomes-in-cardiac-and-thoracic-surgery-100301866","NCT03209674","Registry for the Improvement of Postoperative OutcomeS in Cardiac and Thoracic surgEry","RIPOSTE","Inclusion Criteria:\n\n* all patients eligible for cardiac or thoracic surgery\n\nExclusion Criteria:\n\n* non applicable",{"count":112,"type":21},8000,"2 Months","The registry for the improvement of postoperative outcomes in cardiac and thoracic surgery aims to prospectively collect data in order to test the association between various preoperative and per-operative variables ; and several postoperative outcomes such as mortality, shock, redo surgery, sepsis and extracorporeal life-support.",[116,29,92,117],"Heart Diseases","Cardiac Complication",[119,120],"Cardiac surgery","Thoracic surgery","2026-04-02",{"date":123,"type":34},"2026-04-03",{"date":125,"type":34},"2012-01-01",{"date":127,"type":21},"2030-12-31",{"name":129,"class":41},"CMC Ambroise Paré",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":139,"conditions":140,"keywords":154,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100629619","non-invasive-detection-and-preservation-of-neurocognitive-signals-in-the-peri-death-period-using-brain-computer-interface-and-artificial-intelligence-100629619","NCT07477028","Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence","Feasibility of Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence: A Prospective Observational Study (NeuroCogPresv)","NeuroCogPresv","Inclusion Criteria:\n\n1. Adults ≥18 years with terminal illness or severe acute trauma\n2. Do-not-resuscitate (DNR\u002FDNI) order in place\n3. Surrogate decision-maker available and willing to provide informed consent\n4. Expected survival ≤7 days (physician estimate)\n\nExclusion Criteria:\n\n1. Brain death already declared \\> 24 hours prior to enrollment\n2. Contraindication to EEG\u002FBCI headset placement (e.g., severe scalp injury)\n3. Patient lacks a legally authorized representative",{"count":42,"type":21},"Background: Recent electroencephalography (EEG) data indicate that the transition from clinical death to cellular death is marked by highly organized neurophysiological events, including significant surges in gamma-band power, cross-frequency coupling, and distinct spreading depolarization waves. This prospective, observational feasibility study utilizes rapid-deployment, high-density, noninvasive BCI hardware paired with proprietary AI analytics to detect, classify, and securely archive these terminal neurocognitive signals.\n\nObjectives: (1) Quantify transient gamma-band activity and cross-frequency connectivity post-clinical death; (2) Validate the efficacy of machine learning models for real-time signal classification in high-noise clinical environments; (3) Establish a highly secure, encrypted bio-informational archive of peri-life EEG data.\n\nDesign: Prospective, open-label, multicenter, observational cohort (n\\>20).",[141,142,29,143,144,145,146,147,148,149,150,151,152,153],"Terminal Illness","End-of-Life Care","Brain Death","Death Anxiety","Consciousness","Electroencephalography","Gamma Oscillations","Near-Death Phenomena","Cognitive","Cognition","Memory","EEG","Severe Acute Trauma",[155,156,157,29,147,150,145,158,159,160,151,161,162,163,164],"AI","BCI","Brain Computer Interface","Pefi-death","Brain death","Reservation","Life","Life experience","Transfer","Convergence","NOT_YET_RECRUITING","2026-03-12",{"date":168,"type":34},"2026-03-17",{"date":170,"type":21},"2026-09-01",{"date":172,"type":21},"2035-09-30",{"name":174,"class":175},"Noah Tech, Corp.","INDUSTRY",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":183,"enrollmentInfo":184,"targetDuration":183,"studyType":89,"phases":4,"briefSummary":186,"conditions":187,"keywords":195,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":78},"100613980","characterization-of-extracellular-vesicles-from-the-cord-blood-of-extremely-preterm-new-borns-and-their-correlation-with-severe-morbidity-and-mortality-100613980","NCT07273643","Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With Severe Morbidity and Mortality","VEEP","Inclusion Criteria:\n\n* Mother over 18 years old, able to speak and understand French\n* Newborn less than 28 weeks of gestation, born and hospitalized at Montpellier University Hospital\n* Umbilical cord venous blood collected immediately after birth (from the segment between the cord clamp and the placenta), with a volume of 10 ml (which can be reduced to 3 ml if collection is difficult) into an EDTA tube.\n* Parental non-opposition to the study obtained before sample collection\n\nExclusion Criteria:\n\n* Stillborn infant\n* Handling failure: failure to collect the sample or start the first centrifugation more than 3 hours after birth\n* General regulatory criteria: failure to obtain parental non-opposition, lack of social security coverage, individuals under legal guardianship, or participation in another ongoing research study with an active exclusion period","3 Months",{"count":185,"type":21},30,"This study aims to understand the role of extracellular vesicles (EVs) in extremely premature infants, those born before 28 weeks of gestation. EVs are tiny particles released by cells that carry important information about the body's condition. In extremely premature infants, blood vessels may not function properly, leading to serious health problems such as bleeding in the brain, lung injury, or severe infections.\n\nResearchers believe that analyzing EVs in the umbilical cord blood of these infants may help predict which babies are at higher risk of developing these complications. By studying the size, number, and type of EVs, the team hopes to identify early markers that can guide doctors in providing better care.\n\nThe study will collect cord blood from 30 eligible infants born at the CHU of Montpellier. Blood samples will be processed to isolate platelet-poor plasma, which contains EVs. This plasma will be stored in a biobank, allowing future research on EVs and their role in extreme prematurity. EVs will then be analyzed in the laboratory to assess their characteristics and any links to severe health issues.\n\nThe findings from this study could improve understanding of circulatory problems in extremely premature infants, help identify early predictors of severe complications, and inform better monitoring and treatment strategies. The creation of a plasma biobank also provides a valuable resource for future research to enhance care and outcomes for this vulnerable population.",[188,189,29,190,191,192,193,194],"Intraventricular Hemorrhage","Pulmonary Hemorrhage","ELGAN (22-28SA)","Bronchopulmonary Dysplasia (BPD)","Shock","Extracellular Vesicles","Enterocolitis, Necrotizing",[196,197,198,199,200,201,28],"ELGAN","Extremely Low Gestational Age Newborn (ELGAN)","Extracellular vesicles","EVs","Intraventricular hemorrage","Pulmonary hemorrhage","2026-02-19",{"date":204,"type":34},"2026-02-23",{"date":206,"type":34},"2026-01-13",{"date":208,"type":21},"2027-10-13",{"name":210,"class":41},"University Hospital, Montpellier",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":217,"sex":16,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":222,"studyType":89,"phases":4,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":235,"locationsCount":4},"100608081","prospective-cohort-of-integrated-traditional-chinese-and-western-medicine-in-china-100608081","NCT07196917","Prospective Cohort of Integrated Traditional Chinese and Western Medicine in China","Inclusion Criteria:\n\nAge: Participants aged 30 to 74 years\n\nPhysical Functionality: Free from severe physical disabilities impacting mobility or communication, with preserved ability to comprehend and respond to study procedures\n\nInformed Consent: Capable of providing written informed consent voluntarily after receiving full study disclosure\n\nExclusion Criteria:\n\nResidents living in functional areas (e.g., work sheds, military units, student dormitories, nursing homes, etc.)\n\nIndividuals unable to communicate normally",true,"30 Years","74 Years",{"count":221,"type":21},1000000,"10 Years","To further explore the application prospects of integrated Traditional Chinese and Western medicine in chronic disease prevention and control and health management, this study intends to establish a large, prospective, integrated Traditional Chinese and Western medicine cohort in Hubei Province. This study will conduct long-term follow-up and multi-dimensional data collection to systematically reveal the associations between Traditional Chinese Medicine (TCM) constitution types and chronic diseases, the aging process, and multi-morbidity, thereby developing an integrated health management strategy with local characteristics. This study will fill the current gap in systematic evidence linking TCM constitutions to the prevalence of modern diseases, providing a solid demographic and biological foundation for the integrated development of Traditional Chinese and Western medicine. It will also contribute to meeting the needs for early disease warning, early intervention, and personalized care under the \"Healthy China\" strategic goal.",[225,226,227,228,29],"Cardiovascular Diseases","Respiratory Tract Diseases","Cancer","Endocrine System Diseases","2025-09-29",{"date":231,"type":34},"2025-10-02",{"date":233,"type":21},"2025-10-01",{"date":38,"type":21},{"name":236,"class":41},"Huazhong University of Science and Technology",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":16,"minAge":245,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":248,"conditions":249,"keywords":254,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":78},"100605133","the-rhabdomyolysis-evaluation-in-the-emergency-department-reed-score-100605133","NCT07158554","The Rhabdomyolysis Evaluation in the Emergency Department (REED) Score","The Rhabdomyolysis Evaluation in the Emergency Department (REED) Score - a Risk Prediction Model for Older Adults in the Emergency Department With Rhabdomyolysis After Prolonged Immobilisation (\"Long Lie\")","The REED Score","Inclusion Criteria:\n\nThe participants need to fulfil all three parts of the inclusion criteria:\n\n1. 60 years old or older at time of ED presentation\n2. Developed rhabdomyolysis (defined as CK \\>999U\u002FL)\n3. Have had a fall and been \u002F suspected to have been on the floor \u002F immobilised in one position for \\> 59 minutes.\n\nExclusion Criteria:\n\n1. Patient opted out of research studies via the National Data Opt Out (NDOO) Service.\n2. Principal Investigator (PI) had clinical input into patient care.\n3. Other causes of elevated creatine kinase (e.g. seizures, acute coronary syndromes, burns, myositis, muscular dystrophy, cardiac arrest)","60 Years",{"count":247,"type":21},1000,"One in three adults over 65 fall annually, with one in five remaining on the floor for greater than one hour, which is referred to as a long lie. Pressure on the National Health Service has resulted in extended stays in the Emergency Department (ED) (sometimes longer than 12 hours) and prolonged ambulance response times. This impacts the older adults who have fallen and remain on the floor.\n\nThis project aims to develop a risk prediction model (RPM) for use within the ED to understand which older adults (60 years or older) who fall over and remain on the floor for longer than one hour (\"long lie\") and develop rhabdomyolysis (a serious condition where muscle breaks down and releases substances into the blood that can damage the kidneys) will develop poor outcomes and need admission to hospital for treatment and which patients can be safely discharged home.\n\nAim:\n\nTo develop a RPM to identify which older adults who have a fall and a long lie and attend the ED develop poor outcomes such as Acute kidney Injury (AKI) \\[kidneys suddenly stop working properly\\], needing kidney replacement therapy (KRT) \\[a treatment that helps kidneys that aren't working properly do their job of cleaning the blood\\] and mortality \\[death\\].\n\nObjectives:\n\n1. Abstract patient level data (e.g. biochemical, demographic, situational, medical history, medication history) from medical records combined with outcomes to understand which variables lead to poor outcomes such as AKI, needing KRT and mortality.\n2. Analyse the data using a statistical package (Statistical Package for Social Sciences \\[SPSS\\]) to develop a RPM with good discriminative abilities \\[how well the score can tell high-risk from low-risk patients\\].\n3. Demonstrate the ability of the RPM to identify which patients need admission to hospital with treatment and which patients can be safely discharged home.",[250,29,251,252,253],"Rhabdomyolysis","Kidney Replacement Therapy","Fall Patients","Acute Kidney Injury",[243,250,255,256],"Emergency Department","Long Lie","2025-09-10",{"date":259,"type":34},"2025-09-17",{"date":261,"type":21},"2025-10",{"date":263,"type":21},"2026-04",{"name":265,"class":41},"University of Salford",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":272,"maxAge":245,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":78},"100586484","comparison-between-interleukin-6-and-procalcitonin-in-detecting-sepsis-and-incidence-of-mortality-in-burn-icu-patients-100586484","NCT06915974","Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients","Inclusion Criteria:\n\n* Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence.\n* patients with burn percentage of 25% to 50% of total body surface area\n* patients with second to third degree burns\n* ASA 1 and ASA 2 patients\n\nExclusion Criteria:\n\n* Burn percentage more than 50% or less than 25% of total body surface area\n* Having autoimmune diseases\n* Cancer patients\n* ASA 3 and ASA 4 patients","25 Years",{"count":274,"type":21},70,[24],"The investigators will compare the efficacy of Interleukin-6 (IL-6) as a better indicator than procalcitonin in burn patients with sepsis or septic shock regarding success of treatment and early ICU discharge.",[278,279,280,29],"Burns","Sepsis","Septic Shock","2025-04-04",{"date":283,"type":34},"2025-04-08",{"date":285,"type":34},"2025-01-10",{"date":287,"type":21},"2025-07-10",{"name":289,"class":41},"Ain Shams University",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":296,"targetDuration":298,"studyType":89,"phases":4,"briefSummary":299,"conditions":300,"keywords":304,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":78},"100583795","mini-crush-or-controlled-balloon-crush-for-true-coronary-bifurcation-lesions-100583795","NCT06880978","Mini-Crush Or Controlled Balloon-Crush For True Coronary Bifurcation Lesions","Inclusion Criteria:\n\n* Aged \\>18\n* PCI with mini-crush or controlled balloon-crush\n* Complex coronary bifurcation lesion (Medina 0.1.1 and Medina 1.1.1)\n\nExclusion Criteria:\n\n* Non-complex bifurcation anatomy\n* Bail-out 2-stent (reverse mini-crush or reverse controlled balloon-crush)\n* ST-elevation myocardial infarction\n* Cardiogenic shock status\n* In-stent restenosis\n* A history of coronary artery bypass grafting\n* Implantation of bare-metal stent\n* End-stage hepatic or renal disease\n* \\\u003C1-year life expectancy",{"count":297,"type":21},400,"12 Months","The mini-crush technique is one of the leading 2-stent techniques frequently applied by interventional cardiologists to treat complex bifurcation lesions. In the last 20 years, many technical innovations and iterations of mini-crush technique have been developed, and it maintains its popularity among invasive cardiologists. Moreover, mini-crush and double kissing-crush techniques have been compared in terms of clinical results in both left main and non-left main coronary bifurcation patient populations and no significant difference was found. However, the most important challenges of the mini-crush technique are the rewiring and advancement of a 1:1 non-compliant side-branch balloon after the main branch stent has been implanted. These challenges usually necessitate the use of a low profile balloon or additional support maneuvers (such as anchor balloon). Recently, a novel modified mini-crush-crush technique (controlled balloon-crush) has been introduced to the literature and is one of the most up-to-date crush techniques. The main advantage of this technique over the contemporary mini-crush technique is that the side branch can be easily rewired and the 1:1 size non-compliant balloon can easily pass through the crushed stent structure in the ostial part of the side branch. The basic rationale of this is that the crushing of the side branch stent is done in a more controlled manner (by slowly deflation of the side branch stent balloon) and this causes less disruption of the stent cells. This prospective observational study aims to assess the procedural and 1-year clinical outcomes of the contemporary mini-crush and controlled balloon-crush (modified mini-crush) double stenting techniques in patients with true coronary bifurcation lesions.",[301,29,302,303,57],"Coronary Bifurcation Lesions","Myocardial Infarction (MI)","Stent Thrombosis",[305,306,307,308],"Coronary bifurcation","death","revascularization","stenting","2025-03-17",{"date":311,"type":34},"2025-03-18",{"date":313,"type":34},"2025-03-03",{"date":315,"type":21},"2026-08-01",{"name":317,"class":77},"Istanbul Mehmet Akif Ersoy Educational and Training Hospital",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":217,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":326,"conditions":327,"keywords":330,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":4},"100581599","understanding-death-cultural-factors-affecting-nursing-students-perception-100581599","NCT06852404","Understanding Death: Cultural Factors Affecting Nursing Students' Perception","Understanding Death: The Impact of Cultural Factors on Nursing Students' Perception of Death","Inclusion Criteria:\n\n* Be a third-year student in the Nursing Department of a Health Sciences Faculty at a university in Ankara during the 2024-2025 academic year\n* Own a smartphone capable of taking photographs\n* Be willing to participate in the study.\n\nExclusion Criteria:\n\n* Students who wish to withdraw from the study at any stage will not be included in the research.",{"count":42,"type":21},"Cultural factors play a key role in shaping individuals' perceptions of death, alongside personal beliefs, professional experience, and education. Nursing students must balance their personal and cultural values with their professional responsibilities, as cultural differences influence attitudes toward death and mourning. Understanding nursing students' perceptions of death is crucial for enhancing their education and professional competence. Integrating cultural perspectives into nursing education can help students develop a more conscious and prepared approach to end-of-life care. This study aims to explore the impact of cultural factors on nursing students' perceptions of death and propose strategies to enhance cultural sensitivity in education.",[328,29,329],"Nursing Education","Cultural Factors",[331,332,306,333],"cultural factors","transcultural care","nursing students","2025-02-25",{"date":336,"type":34},"2025-02-28",{"date":338,"type":21},"2025-03-15",{"date":340,"type":21},"2025-06-15",{"name":342,"class":41},"Ankara University",{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":354,"conditions":355,"keywords":363,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":379},"100491430","phase-3-stroke-prophylaxis-with-apixaban-in-chronic-kidney-disease-stage-5-patients-with-atrial-fibrillation-100491430","NCT05679024","Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation","SACK","Inclusion Criteria:\n\n1. Signed Written Informed Consent\n2. 18 years of age or older\n3. Ongoing treatment with any chronic dialysis treatment OR an estimated glomerular filtration rate (eGFR)\\* \\\u003C20 ml\u002Fmin\u002F1.73 m2 at least twice 3 months apart of which at least one occasion is \\\u003C15 ml\u002Fmin\u002F1.73 m2 due to CKD during the last year (12 months).\n4. Diagnosis of chronic (i.e., repeated) paroxysmal, persistent, or permanent atrial fibrillation (AF) or atrial flutter (AFL)\n5. CHA2DS2-VASc score ≥2 or more for men ≥3 or more for women as an indication for oral anticoagulation\n6. Women of childbearing potential (WOCBP) should have a negative highly effective pregnancy test at screening and must agree to follow instructions for method(s) of contraception for the duration of treatment\n\nExclusion Criteria:\n\nParticipants may not be included in the study if any of the following criteria are met:\n\n1. AF or AFL due to reversible causes (e.g., thyrotoxicosis, pericarditis)\n2. Any degree of rheumatic mitral stenosis or moderate-to-severe non-rheumatic mitral stenosis at the time of inclusion into the study\n3. Any condition other than AF or AFL that requires chronic anticoagulation (e.g., a prosthetic mechanical heart valve, antiphospholipid syndrome).\n4. Any contraindication for anticoagulation including\n\n   1. endocarditis\n   2. documented intolerance for apixaban\n   3. liver disease with documented coagulation disorder\n   4. pregnancy or breast feeding\n5. Active bleeding or serious bleeding within 3 months, or\n\n   1. documented hemorrhagic blood dyscrasia\n   2. patients currently receiving dual antiplatelet therapy\n6. Planned for surgery\n\n   1. kidney transplantation with a living donor within 3 months\n   2. active on the kidney transplant waiting list at a kidney transplant center where apixaban use is prohibited\n   3. valvular heart disease surgery\n7. Current use of strong inhibitors of both CYP3A4 and P-glycoprotein in accordance with the summary of product characteristics (SmPC) of apixaban or regular intake of non-steroidal anti-inflammatory drugs (NSAID) or cyclooxygenase-2 (COX2) inhibitors\n8. Any condition or circumstance in which the patient should not participate in the study according to the study investigator (reason documented in the pre-screening protocol)\n\nBeing active on the kidney transplant waiting list is not an exclusion criterion if it is allowed according to the current clinical guidelines at the transplant clinic where the patient is registered. The patient must report changes in waiting list status to the investigator promptly.",{"count":351,"type":21},1400,[353],"PHASE3","Objective: To study the efficacy and safety of apixaban as stroke prophylaxis in patients with chronic kidney disease (CKD) stage 5 and atrial fibrillation (AF) with or without dialysis treatment. The study hypothesis is that compared to no anticoagulation, apixaban reduces the incidence of ischemic stroke without causing an unacceptable increase in fatal or intracranial bleeding events.\n\nThe secondary objectives are to evaluate the risk of all-cause mortality, cardiovascular events, and major bleeding in people with CKD stage 5 and AF treated with apixaban compared to standard of care without anticoagulation.\n\nTrial design: Pragmatic Prospective Open Label Randomized Controlled Clinical Trial, phase 3b over 12-72 months.\n\nTrial population: 1000-1400 patients at ≈50 sites in Sweden, Finland, Norway, Iceland and Poland Eligibility criteria: Adults ≥18 years with CKD stage 5 (ongoing treatment with any chronic dialysis treatment OR an estimated glomerular filtration rate (eGFR)\\* \\\u003C20 ml\u002Fmin\u002F1.73 m2 at least twice 3 months apart of which at least one occasion is \\\u003C15 ml\u002Fmin\u002F1.73 m2 due to CKD during the last 12 months) and a diagnosis of chronic, paroxysmal, persistent, or permanent AF or atrial flutter (AFL) with CHA2DS2-VASc score ≥2 for men or ≥3 or more for women as an indication for oral anticoagulation.\n\nThe exclusion criteria are AF or AFL due to reversible causes, rheumatic mitral stenosis or moderate-to-severe non-rheumatic mitral stenosis at the time of inclusion into the study, a condition other than AF or AFL that requires chronic anticoagulation, contraindications for anticoagulation, active bleeding or serious bleeding within 3 months, planned for surgery within 3 months, and current use of strong inhibitors of both CYP3A4 and P-glycoprotein.\n\nInterventions: Randomization 1:1 to treatment with apixaban 2.5 mg twice daily and standard of care, or standard of care and no anticoagulation.\n\nOutcome measures: primary efficacy (time to first ischemic stroke); primary safety (the composite of time to first intracranial bleeding or fatal bleeding); secondary efficacy (time to all-cause mortality, time to cardiovascular event or cardiovascular death); secondary safety (time to first major bleeding according to International Society on Thrombosis and Hemostasis (ISTH) criteria)",[356,357,57,358,359,360,29,361,362],"Chronic Kidney Diseases","Atrial Fibrillation","Intracerebral Hemorrhage","Major Bleed","Cardiovascular Complication","Kidney Transplant; Complications","Thromboses, Venous",[364,365,366,367,368,369],"Chronic kidney disease","Hemodialysis","Peritoneal dialysis","Kidney transplantation","Atrial fibrillation","Oral anticoagulation","2024-10-02",{"date":372,"type":34},"2024-10-04",{"date":374,"type":34},"2023-02-17",{"date":376,"type":21},"2028-12-31",{"name":378,"class":77},"Region Stockholm",34,{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":387,"targetDuration":389,"studyType":89,"phases":4,"briefSummary":390,"conditions":391,"keywords":396,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":4},"100560951","incidence-and-complications-of-post-extubation-and-post-tracheostomy-dysphagia-in-adult-patients-in-the-critical-care-unit-100560951","NCT06583824","Incidence and Complications of Post-extubation and Post-tracheostomy Dysphagia in Adult Patients in the Critical Care Unit","Incidence and Complications Associated with Acquired Swallowing Disorder in the Intensive Care Unit in Extubated or Tracheotomized Patients: a Cohort Study","Inclusion Criteria:\n\nPatients aged ≥ 18 years, requiring intubation for ≥ 48 hours and\u002For subsequent tracheostomy, with an adequate level of consciousness to perform the dysphagia diagnostic test, and who have signed the consent form.\n\nExclusion Criteria:\n\nPrevious tracheostomy, prior diagnosis of dysphagia, neurodegenerative disease, or a history of stroke (CVA).",{"count":388,"type":21},414,"6 Months","Acquired Swallowing Disorder in ICU (ICU-ASD), also known as postextubation dysphagia, is a multicausal problem experienced by survivors in intensive care units (ICUs) when the efficiency, safety of swallowing, or both are compromised. These alterations can lead to an increased risk of aspiration, respiratory complications, and malnutrition, potentially resulting in prolonged hospitalization, reduced quality of life, poorer clinical outcomes, and even death.\n\nDespite the clinical and social significance of this disorder, there is limited research addressing it. Existing studies primarily focus on incidence and associated factors, with scant attention to the occurrence of complications, and there is a lack of assessment of the quality of life of these patients. In our context, healthcare professionals are increasingly recognizing the importance of this issue, although the real incidence of ICU-ASD, as well as the frequency of respiratory and nutritional complications, remains unknown. Furthermore, the quality of life of patients with this disorder has not been evaluated thus far.\n\nObjectives:Primary: To analyze the occurrence of respiratory and nutritional complications associated with ICU-ASD in patients intubated for ≥48 hours or tracheotomized in the Intensive Care Unit of the University Hospital Complex of Albacete (ICU CHUA) and identify potential factors related to their occurrence.\n\nSpecific: To determine the incidence of ICU-ASD in the polyvalent ICU CHUA, assess the frequency of respiratory complications, evaluate nutritional status, assess quality of life, and determine the mortality of study participants.\n\nMaterial and Method: Prospective observational cohort study. Setting: Polyvalent ICU CHUA. Participants: Intubated patients for ≥48 hours or tracheotomized, with signed consent. Sampling: Consecutive. Sample size: 414 participants. Demographic\u002Fclinical variables. Outcome variables: Occurrence of respiratory complications, nutritional status, quality of life. Instruments: Modified Volume-Viscosity Swallowing Test (mV-VST), Swallowing Quality of Life Questionnaire (SWAL-QoL). Dysphagia detection will occur 24 hours post-extubation and\u002For 4 days after tracheotomy. Follow-up during hospitalization and post-ICU discharge until the outpatient consultation. Statistical analysis: Absolute and relative frequencies, measures of central tendency and dispersion, significance level of p \\< 0.05, 95% CI; Bivariate analysis: Checking group homogeneity and hypothesis testing: Chi-square, Student\\'s t-test, U-Mann-Whitney, ANOVA, or Kruskal-Wallis.",[392,393,394,29,395],"Respiratory Complications","Pneumonia","Quality of Lifte","Swallowing Disorder.Other Specified",[397,398,399,400,401,402,403],"dysphagia","tracheostomy","aspiration","malnutrition","critical care","mechanical ventilation","pneumonia","2024-09-03",{"date":406,"type":34},"2024-09-04",{"date":408,"type":21},"2024-09-10",{"date":410,"type":21},"2026-09-30",{"name":412,"class":41},"Complejo Hospitalario Universitario de Albacete",{"id":414,"slug":415,"hasResults":11,"nctId":416,"briefTitle":417,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":217,"sex":16,"minAge":245,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":422,"conditions":423,"keywords":427,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":78},"100552406","china-healthy-aging-cohort-study-100552406","NCT06472674","China Healthy Aging Cohort Study","China-Ageing","Inclusion Criteria:\n\n* Aged 60 years or older\n* Lived in the community for more than 1 year\n* Signed the informed consent form\n\nExclusion Criteria:\n\n* Cannot complete the survey",{"count":421,"type":21},6780,"This is a community-based prospective cohort study in China. The study has been initialized in 2024 and included older residents. The goal of this observational study is to explore the risk factors related to disability and dementia in the elderly Chinese community population, and develop a risk prediction model for disability and dementia.",[424,425,426,29],"Age Problem","Disability","Dementia",[428],"Disability, Dementia, Ageing, Cohort","2024-06-23",{"date":431,"type":34},"2024-06-25",{"date":433,"type":34},"2024-06-13",{"date":435,"type":21},"2063-06",{"name":437,"class":41},"Xuanwu Hospital, Beijing",{"id":439,"slug":440,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":442,"acronym":443,"eligibilityCriteria":419,"healthyVolunteers":217,"sex":16,"minAge":245,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":446,"conditions":447,"keywords":448,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":78},"100546429","beijing-disability-risk-and-ageing-monitoring-study-100546429","NCT06394817","Beijing Disability Risk and Ageing Monitoring Study","BEAM",{"count":445,"type":21},2000,"This is a community-based prospective cohort study in Beijing, China. The study has been initialized in 2023 and enrolled older residents. This study aims to develop disability risk assessment standards and an early warning model for older adults.",[424,425,29],[449],"Disability, Ageing, Cohort","2024-06-17",{"date":452,"type":34},"2024-06-20",{"date":454,"type":34},"2023-02-20",{"date":456,"type":21},"2063-05",{"name":437,"class":41},{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":16,"minAge":466,"maxAge":467,"enrollmentInfo":468,"targetDuration":4,"studyType":22,"phases":470,"briefSummary":471,"conditions":472,"keywords":477,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":78},"100485728","probiotic-supplementation-in-extremely-preterm-infants-in-scandinavia-100485728","NCT05604846","Probiotic Supplementation in Extremely Preterm Infants in Scandinavia","Probiotic Supplementation in Extremely Preterm Infants in Scandinavia: A Double-blinded Randomized Controlled Multicenter Trial to Reduce the Risk of Necrotizing Enterocolitis and Mortality","PEPS","Inclusion Criteria:\n\n-All extremly preterm infants born beween gestational age 22+0 to 27+6\n\nExclusion Criteria:\n\n* Patients with severe complications and low chance of survival detected wihin the first 72 hours of life\n* Patients with major congenital-anomalies\n* Patients included in other interventional trials with the same or overlapping oucome measures.","22 Weeks","28 Weeks",{"count":469,"type":21},1600,[24],"The primary aim of this research is to determine whether supplementation with probiotics during the first weeks of life reduces the risk of necrotizing enterocolitis (NEC) and neonatal mortality and is safe to use among extremely preterm (EPT) infants born before gestational week 28.\n\nP: The study population include EPT infants (n= 1620) born at six tertiary neonatal units in Sweden and four units in Denmark.\n\nI: This is a double-blinded multicenter randomized controlled trial where infants in the intervention group will as soon as they tolerate 3 mL breastmilk per feed receive a probiotic combination of Bifidobacterium infantis, Bifidobacterium lactis, and Streptococcus thermophilus diluted in 3 mL breastmilk and given once daily until gestational week 34.\n\nC: The control group will receive 3 mL breastmilk without probiotic supplementation (blinded) daily.\n\nO: Primary outcome variables is a composite endpoint of incidence of NEC and mortality. Secondary outcomes include incidence of sepsis, duration of hospital stay, use of antibiotics, feeding tolerance, growth, and body composition after hospital discharge.\n\nPatient benefit: To provide evidence on the usage of probiotics among EPT infants that are not currently covered by clinical recommendations. As EPT infants have the highest risk for NEC and mortality our results have the potential to change current recommendations and improve patient outcomes, decrease mortality, shorten hospitalization, and decrease overall health-care costs.",[473,29,474,475,476],"Necrotizing Enterocolitis","Sepsis Newborn","Feeding Disorder Neonatal","Growth Acceleration",[478,479,480,481],"Probiotics","NEC","Extreme prematurity","Feeding tolerance","2023-10-13",{"date":484,"type":34},"2023-10-16",{"date":486,"type":34},"2022-12-16",{"date":488,"type":21},"2026-12",{"name":378,"class":77},{"id":491,"slug":492,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":217,"sex":498,"minAge":4,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":22,"phases":501,"briefSummary":502,"conditions":503,"keywords":509,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":103},"100498174","coupons-for-safe-water-project-100498174","NCT05766826","Coupons for Safe Water Project","Scaling up Coupons for Safe Water Treatment in Kenya","Coupons","Inclusion Criteria:\n\n* Currently pregnant women\n* Women living inside Health and Demographic Surveillance Systems (HDSS) catchment areas.\n\nExclusion Criteria:\n\n\\- Women who do not consent.","FEMALE",{"count":500,"type":21},3468,[24],"Guaranteeing access to safe drinking water is still a challenge in rural households in developing countries, and unsafe water sources are responsible for millions of deaths each year around the world. Coupons for free dilute chlorine solution are a cost-effective and effective way of ameliorating child health and reducing diarrhea incidence. It is still an empirical challenge, however, to see if the positive health effects will be maintained when the program is implemented at scale. In this study, investigators conduct a randomized controlled trial (RCT) at scale to study the impacts of a chlorine coupon program implemented at health clinics on child health, including self-reported diarrhea, fever, and cough incidence in the previous two weeks. Investigators further investigate the pathway of the impact, such as self-reported and objectively measured use of chlorine and frequency of visits to health clinics.",[29,504,505,506,507,508],"Death, Infant","Diarrhea","Diarrhea, Infantile","Water-Borne Infectious Disease","Water-Related Diseases",[510,511,512,513,514,496,515,516,517],"Child health","Child mortality","Chlorine","Safe water","Targeting","RCT","East Africa","Kenya","2023-03-10",{"date":520,"type":34},"2023-03-13",{"date":522,"type":34},"2023-02-21",{"date":524,"type":21},"2026-10-01",{"name":526,"class":41},"University of Chicago",{"id":528,"slug":529,"hasResults":11,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":11,"sex":16,"minAge":535,"maxAge":536,"enrollmentInfo":537,"targetDuration":4,"studyType":22,"phases":539,"briefSummary":540,"conditions":541,"keywords":545,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":103},"100448262","enteral-feeding-in-infants-with-duct-dependant-lesions-100448262","NCT05117164","Enteral Feeding in Infants With Duct Dependant Lesions.","Effect of Standardised vs Local Preoperative Enteral Feeding Practice on the Incidence of NEC in Infants With Duct Dependent Lesions: a Randomised Control Trial.","CARDIOFEED","Inclusion criteria:\n\n1. Duct dependent congenital heart disease\n2. Term infants\n3. Parental\u002Flegal guardian consent\n\nExclusion criteria:\n\n1. Potential contradictions to early central feeding\n2. Feeding intolerance\n3. Hemodynamic instability\n4. Death\n5. \\> 50% formula based enteral feeding\n6. Birth weight less than 2500g","1 Minute","72 Hours",{"count":538,"type":21},384,[24],"This is a multicenter randomised controlled trial to assess whether standardised enteral feeding in newborns with duct dependenty congenital heart disease decreases the risk of necrotising enterocolitis (NEC). The investigators plan to include a total 384 infants. The study will be carried out in three level III hospitals in Poland. The primary end will be NEC and\u002For death. Secondary end points include weight gain, hospital length of stay, time required to reach full feeding.",[542,543,29,544],"Duct Dependent Lesions","Necrotising Enterocolitis","Growth",[546,547,548,549],"congenital heart disease","nutrition","growth","newborn","2022-07-16",{"date":552,"type":34},"2022-07-20",{"date":554,"type":21},"2022-08-10",{"date":556,"type":21},"2026-12-31",{"name":558,"class":41},"Princess Anna Mazowiecka Hospital, Warsaw, Poland",{"id":560,"slug":561,"hasResults":11,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":11,"sex":498,"minAge":245,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":22,"phases":568,"briefSummary":569,"conditions":570,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":588},"100335402","partial-breast-versus-no-irradiation-for-women-with-early-breast-cancer-100335402","NCT03646955","Partial Breast Versus no Irradiation for Women With Early Breast Cancer","The DBCG RT Natural Trial: Partial Breast Versus no Irradiation for Women >=60 Years Operated With Breast Conservation for an Early Breast Cancer: a Clinically Controlled Randomized Phase III Trial","Inclusion Criteria:\n\nFemale patient \\>=60 years\n\nPrimary tumour characteristics by conventional histopathology\n\n* unilateral and unifocal non-lobular histology grade 1-2\n* maximum microscopic size \\\u003C=20mm\n* node negative determined by sentinel node or axillary lymph node dissection\n* estrogen receptor \\>=10% positive\n* HER2 negative (by IHC and\u002For in situ hybridization)\n* resection margin \\>=2 mm for invasive carcinoma and any ductal carcinoma in situ associated with the cancer\n\nSurgical type is breast conservation\n\nPerformance status ECOG 0-2\n\nNo evidence of distant metastasis\n\nExclusion Criteria:\n\n* multifocal or multicentric invasive carcinoma or ductal carcinoma in situ\n* evidence of clinical or pathological T4 breast cancer\n* grade 3 malignancy\n* previous breast cancer or DCIS irrespective of disease-free interval\n* previous radiation therapy to the breast or thorax,\n* previous neoplasm within 5 years except carcinoma in situ of the cervix, endometrium or coli, melanoma in situ.\n* comorbidity precluding the patient from radiation therapy (e.g. cardiovascular or pulmonary disease, scleroderma, systemic lupus erythematosus).\n* mental\u002Fpsychiatric disorder which precludes the patient from understanding the randomization and the follow up.\n* documented hereditary breast cancer or with high genetic risk of breast cancer\n* life expectancy \\\u003C10 years",{"count":567,"type":21},926,[24],"All early breast cancer patients are offered adjuvant breast radiation therapy (RT) after breast conserving surgery for an early breast cancer. Breast cancer is heterogeneous, and selected patients have a very low gain from RT, whilst they still have risk of acute and late side effects from RT. This trial will try identify selection criteria for low risk breast cancer patients who can safely omit adjuvant RT without unacceptable high risk of local failure.",[571,572,29,573,574,575,576,577,578],"Local Neoplasm Recurrence","Distantly Metastatic Malignant Neoplasm","Fibrosis Breast","Depigmentation\u002FHyperpigmentation of Skin","Telangiectasia","Scar","Pain","PROMs","2020-10-05",{"date":581,"type":34},"2020-10-06",{"date":583,"type":34},"2018-09-05",{"date":585,"type":21},"2035-09-01",{"name":587,"class":41},"Danish Breast Cancer Cooperative Group",17,{"id":590,"slug":591,"hasResults":11,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":217,"sex":16,"minAge":597,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":600,"conditions":601,"keywords":608,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":103},"100329477","nanshan-elderly-cohort-study-100329477","NCT03569735","Nanshan Elderly Cohort Study","Nanshan Elderly Cohort Study：a Community-based Prospective Cohort Study in Nanshan， Shenzhen Residents","NECS","Inclusion Criteria:\n\n* Age: ≥ 65 years;\n* Living in Nanshan, Shenzhen for at least 5 years;\n* Chinese.\n\nExclusion Criteria:\n\n* Had a history of hospital-confirmed diabetes, failure(s) of heart, liver, or kidney, cancer, CVD events;\n* On special diet due to a disease or weight control;\n* Mental and physical disability;\n* Likely to move to other city within 5 years;\n* Did not want to attend any one item of the survey or sample collection.","65 Years",{"count":599,"type":21},20000,"Objective: The Nanshan Elderly Cohort Study (NECS) aims to investigate the nutritional, as well as other environmental and genetic factors of chronic diseases, such as cardio-metabolic diseases.\n\nStudy design: NECS is a community-based prospective cohort study. Participants: About 10000-20000 apparently healthy residents, living in Nanshan， Shenzhen (South China) for \\>5 years, aged ≥ 65 years, will be recruited between 2018 and 2019.\n\nVisits and Data Collection: Participants will be followed up approximately every 3 years by invited to the Community Healthcare Service Centre. At each survey, face-to-face interviews, anthropometric measurements, ultrasonography examination, electrocardiogram test and specimen collection will be conducted.\n\nKey variables:\n\n1. Face-to-face interviews: Structured questionnaires will be used to collect the participants' socio-demographic characteristics, lifestyles, habitual dietary intake, physical activity, history of chronic diseases, use of supplements and medications, family history, psychological health and cognitive function.\n2. Physical examinations: Anthropometric measurements, blood pressure tests, handgrip strength, and usual gait speed.\n3. Ultrasonography examinations: Ultrasonography examination will be performed to determine carotid artery intima-media thickness and plaque, fatty liver.\n4. Electrocardiogram test: Electrocardiogram test is to obtain information about the structure and function of the heart.\n5. Specimen collections: Overnight fasting blood sample, early morning first-void urine sample and faeces samples will be collected and stored at -80°C till tests.\n6. Laboratory tests:\n\n   1. Blood tests: Metabolic syndrome-related indices; nutritional indices; inflammatory markers; sexual hormones; genetic markers.\n   2. Urinary tests: Flavonoids and flavones, minerals, creatinine and renal function related markers.\n   3. Fecal test: Gut microbiota and related metabolites.\n7. Morbidity and mortality: Relevant data will be also retrieved via local multiple Health information systems.\n8. Others: Many other laboratory tests or instrument tests will be developed depended on needs and resources in future.",[602,603,225,57,604,605,606,607,227,29],"Hypertension","Type 2 Diabetes Mellitus","Obesity","Metabolic Syndrome","Sarcopenia","Chronic Kidney Disease",[609,610,611,612,613],"Prospective Cohort Study","Nutrition","Chronic diseases","Nanshan","Chinese","2018-06-23",{"date":616,"type":34},"2018-06-26",{"date":618,"type":34},"2018-05-26",{"date":620,"type":21},"2028-12-30",{"name":622,"class":41},"Sun Yat-sen University",{"id":624,"slug":625,"hasResults":11,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":629,"eligibilityCriteria":630,"healthyVolunteers":11,"sex":16,"minAge":597,"maxAge":4,"enrollmentInfo":631,"targetDuration":222,"studyType":89,"phases":4,"briefSummary":632,"conditions":633,"keywords":642,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":4},"100251946","european-transplant-registry-of-senior-renal-transplant-recipients-on-advagraf-100251946","NCT02558452","European Transplant Registry of Senior Renal Transplant Recipients on Advagraf","European Transplant Registry of Senior Renal Transplant Recipients Receiving Initial Immunosuppression With Tacrolimus Once Daily, Mycophenolate and Steroids","SENIOR","Inclusion Criteria:\n\n* Males or females, aged ≥65 years\n* Patients who received a renal allograft\n* Patients who are willing and able to participate in the study and from whom written informed consent has been obtained\n* Patients on an intended standard triple therapy with tacrolimus once daily (Advagraf with trough level ≥5ng\u002Fml) in combination with mycophenolate (either ≥1.0g\u002Fday MMF or ≥720mg\u002Fd EC-MPS) and Steroids (≥5mg prednisolone or equivalent)\n* Patient must have received primary or secondary renal allograft from a blood group compatible donor (either deceased or living)\n* Patients with low to standard immunological risk, who had a PRA 20% (PRA testing according to center's practice) or no known donor specific antibodies at transplantation\n\nExclusion Criteria:\n\n* Multi-organ recipients (solid organ or bone marrow)\n* More than secondary renal allograft recipients\n* Blood group A,B,O-incompatible allografts\n* Documented presence of donor specific antibodies (DSA)\n* Panel reactive antibody (PRA) \\>20% prior to transplantation (PRA testing according to center's practice)\n* Patients having received any other induction therapy than Basiliximab or depleting polyclonal antithymocyte antibodies (ATG) (e.g. OKT3, Campath)\n* Patients receiving Sirolimus, Everolimus, Azathioprine, Belatacept or Cyclophosphamide within 3 months prior to or at enrolment\n* History of alcohol or drug abuse with less than 6 months of sobriety\n* Patient with any condition that may affect absorption of immunosuppressives, (e.g. severe diarrhoea, gastrectomy, active peptic ulcer disease or clinically significant diabetic gastroenteropathy) or tacrolimus metabolism (e.g. liver cirrhosis)\n* Patient with mental dysfunction or inability to cooperate within the study\n* Patients who have been institutionalized by official or court order",{"count":247,"type":21},"SENIOR transplant Registry European transplant registry of senior renal transplant recipients (above the age of 65 years) receiving initial immunosuppression with tacrolimus once daily, mycophenolate and steroids to investigate long term outcomes on an observational basis.",[634,29,635,636,637,638,93,639,640,641],"Graft Failure","Acute Rejection of Renal Transplant","Infections","Bone Disease","Post Transplant Diabetes Mellitus","HLA Antibody Production","Cardiovascular Risk Factors","Non-HLA Antibody Production",[643,644,645],"elderly kidney transplant recipient","registry","tacrolimus once daily","2016-08-11",{"date":648,"type":21},"2016-08-12",{"date":650,"type":4},"2016-12",{"date":652,"type":21},"2028-01",{"name":654,"class":41},"Klemens Budde"]